FAQs on Annovis Bio's US Patent for Treating Acute Traumatic Brain Injury with Buntanetap
Summary
What is buntanetap and what does it treat?
Buntanetap is Annovis Bio’s lead drug candidate, formerly known as Posiphen or ANVS401, designed to treat neurodegenerative diseases by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP43, thereby improving synaptic transmission, axonal transport, and reducing neuroinflammation.
Why is the receipt of U.S. Patent No. 12,042,482 significant for Annovis Bio?
The patent signifies a major milestone for Annovis Bio, as it covers the use of buntanetap in treating acute traumatic brain injuries (TBI) and preventing nerve cell death, expanding its potential application beyond Alzheimer’s and Parkinson’s diseases to include brain trauma.
How does buntanetap work in treating neurodegenerative diseases?
Buntanetap targets neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, which improves synaptic transmission, axonal transport, and reduces neuroinflammation, thereby preventing cell death and loss of function.
Who is the founder and CEO of Annovis Bio?
Maria Maccecchini, Ph.D., is the Founder, President, and CEO of Annovis Bio, who expressed excitement over the patent as a significant milestone for buntanetap.
Where can I find more information about Annovis Bio and its developments?
For more information, visit Annovis Bio’s website at www.AnnovisBio.com, and their social channels on LinkedIn, X, and YouTube. The latest news and updates are also available in the company’s newsroom at https://ibn.fm/ANVS.
What are the implications of this patent for victims of brain trauma?
The patent opens up new possibilities for treating acute traumatic brain injuries with buntanetap, offering hope for preventing nerve cell death and improving outcomes for victims of brain trauma, a prevalent issue in the U.S.
What preclinical studies support the efficacy of buntanetap?
Preclinical studies in TBI and stroke animal models have demonstrated buntanetap’s efficacy in preventing cell death and loss of function, supporting its potential benefits for brain trauma victims.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 131805